Two-thirds of the uk's newly infected COVID-19 people are reinfected Vaccine secondary strengthening strategies are in a dilemma

A new study published in the UK on Wednesday found that more than two-thirds of the 3,582 infected people who have participated in the study since January this year are cases that have been previously infected with COVID-19, creating new challenges for the vaccination strategy of the fourth dose of the vaccine.

The latest research found that between 5 January and 20 January, Omi kerong almost completely replaced Delta, accounting for 99% of positive cases in the UK, becoming the dominant epidemic strain in the UK.

More than two-thirds of those infected who participated in the study reported that they had confirmed COVID-19 infection in the past. British health officials estimated in December that the risk of reinfection caused by Omikeron was 5.4 times that of Delta.

The study is part of React, a large COVID-19 study at Imperial College Uk, and the latest results also show that despite a decline in COVID-19 infections in the UK in early January, cases have since begun to surge and hit record highs, with one in every 23 people infected so far.

As the number of infected people worldwide rises dramatically, manufacturers including Pfizer and Moderna have launched clinical trials of specific vaccines for the Semikeron variant.

Moderna said Wednesday that in the Phase II clinical trial, the first participant had received a booster dose of the Opmi kerong-specific vaccine, and Moderna expects to recruit about 600 adult participants aged 18 and older.

Stephane Bancel, CEO of Moderna, previously predicted that people may need a fourth dose of COVID-19 boosters this fall.

However, given the potential for the virus to continue to mutate, some experts believe that the strategy of continuous vaccination and strengthening the vaccine is not feasible. The French government's Vaccine Strategy Committee (COSV) issued an opinion on Wednesday, writing: "The available data show that there is currently no need for full implementation of secondary vaccine boosters". "Secondary booster" also refers to the fourth dose of booster vaccine.

In its opinion, COSV noted that a third dose of enhancer is still effective in preventing severe COVID-19, even if it is less effective in preventing infection with COVID-19. The committee also said that based on available data, even a fourth dose of booster injection may not be effective in preventing COVID-19 infection.

On the other hand, in the context of the current mass epidemic of Omiljung, the population may already be able to resist future VARIANTs of COVID-19 through natural immunity, which will also reduce the need for secondary vaccine enhancement in the general population.

According to a new forecast published by The Lancet, by March this year, the number of people infected with COVID-19 in Europe may reach more than 50%.

CoSV argues that the promotion of the fourth dose of reinforcement now could "have a counterproductive effect" and could send "a signal that it is easy for public opinion to misinterpret vaccination as ineffective."

However, COSV still believes that people with severe immunocompromise should be given a fourth booster systematically, and a fourth dose of booster injection can be recommended to people over 80 years of age.